Synairgen plc Appointment of New Chief Financial Officer (6997P)
11 October 2023 - 5:00PM
UK Regulatory
TIDMSNG
RNS Number : 6997P
Synairgen plc
11 October 2023
Synairgen plc
('Synairgen' or the 'Company')
Appointment of Joseph Colliver as New Chief Financial
Officer
Southampton, UK - 11 October 2023: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, an investigational
formulation for inhalation containing the immunomodulatory
broad-spectrum antiviral protein interferon beta, today announces
that Joseph Colliver has been appointed Chief Financial Officer
(CFO) and Executive Director with effect from Monday 6 November
2023. In conjunction with this appointment, and following nearly 20
years of loyal service and an orderly handover, John Ward will step
down from the role of CFO and Executive Director on Friday 3
November.
Joseph Colliver has significant financial leadership experience,
including most recently as CFO and non-executive director of
several listed life sciences companies. He has previously held CFO
and senior commercial roles within the Kantar division of WPP PLC.
He also has many years of experience as a consultant and in various
Board roles, with a deep understanding of the strategy, governance
and regulatory requirements of biotechnology companies.
Richard Marsden, CEO of Synairgen, said: "Joseph's many years of
listed company experience, including in the healthcare sector, will
stand us in good stead as we progress towards the clinic with our
SNG001 strategy. I'd like to thank John for his steadfast
commitment, loyalty and support to both me and the Board over many
years. We wish him the very best for the future."
Joseph Colliver, newly appointed CFO of Synairgen, commented :
"This is a pivotal time for the Company, as it works towards the
next phase of clinical trials with SNG001. I look forward to
working closely with Richard and the team in the coming months and
years."
John Ward, outgoing CFO of Synairgen, commented : "It has been a
pleasure to work with the Synairgen team for these many years,
driven by the shared vision to develop treatments for severe viral
lung infections. However, it's the right time to pass on the baton,
and I look forward to following the Company's next steps and wish
the team every success with SNG001 in the future."
Information required under Rule 17 and Schedule Two, paragraph
(g) of the AIM Rules for Companies ("AIM Rules")
Full name: Joseph Tregonning Colliver
Age: 43
Shares held in the Company: None
Current directorships:
* Phytome Life Sciences Plc
* Phytome Research Ltd
* Hellenic Dynamics Plc
* Psych Capital Plc
* Colliver Advisory Ltd
Historic directorships in
previous 5 years: * Sativa Wellness Group Inc
* Borganic Consulting Inc
* Olimax NT Sp z o.o.
* Sativa Group Ltd
* Blood Matters Ltd
* Sativa Cultivation and Extraction Limited
* Sativa Wellness Ltd
* Phytovista Laboratories Ltd
* Goodbody Botanicals Ltd
* Tessellate Collective Ltd
* Goodbody and Blunt Ltd
* Sativa Investments Ltd
* Goodbody Wellness Limited
* George Botanicals Ltd
* Sativa Cosmetics Ltd
There is no further information to be disclosed in relation to
the appointment pursuant to Rule 17 and Schedule Two, paragraph (g)
of the AIM Rules.
For further enquiries, please contact:
Synairgen plc
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
Cavendish Capital Markets Limited (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Sunila de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
Freddie Barnfield, Duncan Monteith, Euan Brown
Tel: + 44 (0) 20 7260 1000
ICR Consilium (Financial Media and Investor Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
Synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
Synairgen is a UK-based respiratory company focused on drug
discovery and the development of SNG001 (inhaled interferon beta)
as potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs for severe viral lung
infections.
Millions of people globally are hospitalised every year due to
viral lung infections and there are currently no approved antiviral
therapies for the majority of these patients. Synairgen is
developing SNG001 to address this need.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABIBDGLUBDGXG
(END) Dow Jones Newswires
October 11, 2023 02:00 ET (06:00 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Dec 2024 to Jan 2025
Synairgen (LSE:SNG)
Historical Stock Chart
From Jan 2024 to Jan 2025
